<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088048</url>
  </required_header>
  <id_info>
    <org_study_id>101-07</org_study_id>
    <nct_id>NCT01088048</nct_id>
  </id_info>
  <brief_title>Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and clinical activity of idelalisib in combination with
      an anti-CD20 monoclonal antibody (mAb), a chemotherapeutic agent, an mTOR inhibitor, a
      protease inhibitor, an antiangiogenic agent, and/or an immunomodulatory agent in participants
      with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL), mantle cell lymphoma
      (MCL), or chronic lymphocytic leukemia (CLL).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Extent of exposure to idelalisib and toxicity</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Extent of exposure to idelalisib and toxicity will be assessed by incidence and severity of adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Rate</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Clinical activity will be evaluated by clinical response rate, assessed by CT scan, clinical laboratory tests, and bone marrow biopsy if indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of idelalisib</measure>
    <time_frame>Predose and 1.5 hour postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of chemotherapeutic agents in a select subset of participants</measure>
    <time_frame>For idelalisib: predose and 0.5, 1, 1.5, 2, 3, 4, and 6 hours postdose; For bendamustine: Predose and 15, 30, 45, 60, 75, 90, 120, 180, 240, 300, and 360 minutes postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of everolimus</measure>
    <time_frame>Predose and 1.5 hour postdose</time_frame>
    <description>This endpoint will only be evaluated for participants in the Idelalisib + Everolimus group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of lenalidomide</measure>
    <time_frame>Predose and 1.5 hour postdose</time_frame>
    <description>This endpoint will only be evaluated for participants in the Idelalisib + Rituximab + Lenalidomide group.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Indolent Non-Hodgkin's Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Idelalisib + Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idelalisib 100 mg or 150 mg twice daily + rituximab 375 mg/m^2 for 8 weekly doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idelalisib + Rituximab + Bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idelalisib 150 mg twice daily + rituximab 375 mg/m^2 on Day 1 + bendamustine 90 mg/m^2 on Days 1 &amp; 2 of Cycles 1-6 for participants with iNHL or MCL. Bendamustine 70 mg/m^2 for for participants with CLL only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idelalisib + Bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idelalisib 100 mg or 150 mg twice daily + bendamustine 90 mg/m^2 or 70 mg/m^2 on Days 1 &amp; 2 of Cycles 1-6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idelalisib + Ofatumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idelalisib 150 mg twice daily + 12 doses of ofatumumab over the course of 6 months. For participants with CLL only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idelalisib + Fludarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idelalisib 150 mg twice daily + oral fludarabine 40 mg/m^2 on Days 1-5 of Cycles 1-6. For participants with CLL only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idelalisib + Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idelalisib 150 mg twice daily + oral everolimus 10 mg once daily. For participants with MCL only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idelalisib + Bortezomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idelalisib 150 mg twice daily + bortezomib 1.3 mg/m^2 once weekly for 3 weeks (Days 1, 8, and 15) followed by a 13-day rest period. For participants with MCL only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idelalisib + Chlorambucil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idelalisib 150 mg twice daily + chlorambucil 10 mg/m^2 on Days 1-7 every 28 days. For participants with CLL only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idelalisib + Rituximab + Chlorambucil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idelalisib 150 mg twice daily + rituximab 375 mg/m^2 + chlorambucil 10 mg/m^2 for participants with CLL only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idelalisib + Rituximab + Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idelalisib 150 mg twice daily + rituximab 375 mg/m^2 + lenalidomide 5, 10 or 20 mg (M.D. Anderson Cancer Center only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib</intervention_name>
    <description>Idelalisib tablet administered orally</description>
    <arm_group_label>Idelalisib + Rituximab</arm_group_label>
    <arm_group_label>Idelalisib + Rituximab + Bendamustine</arm_group_label>
    <arm_group_label>Idelalisib + Bendamustine</arm_group_label>
    <arm_group_label>Idelalisib + Ofatumumab</arm_group_label>
    <arm_group_label>Idelalisib + Fludarabine</arm_group_label>
    <arm_group_label>Idelalisib + Everolimus</arm_group_label>
    <arm_group_label>Idelalisib + Bortezomib</arm_group_label>
    <arm_group_label>Idelalisib + Chlorambucil</arm_group_label>
    <arm_group_label>Idelalisib + Rituximab + Chlorambucil</arm_group_label>
    <arm_group_label>Idelalisib + Rituximab + Lenalidomide</arm_group_label>
    <other_name>GS-1101</other_name>
    <other_name>CAL-101</other_name>
    <other_name>Zydelig®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab administered intravenously</description>
    <arm_group_label>Idelalisib + Rituximab</arm_group_label>
    <arm_group_label>Idelalisib + Rituximab + Bendamustine</arm_group_label>
    <arm_group_label>Idelalisib + Rituximab + Chlorambucil</arm_group_label>
    <arm_group_label>Idelalisib + Rituximab + Lenalidomide</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine administered intravenously</description>
    <arm_group_label>Idelalisib + Rituximab + Bendamustine</arm_group_label>
    <arm_group_label>Idelalisib + Bendamustine</arm_group_label>
    <other_name>Treanda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofatumumab</intervention_name>
    <description>Ofatumumab administered intravenously</description>
    <arm_group_label>Idelalisib + Ofatumumab</arm_group_label>
    <other_name>Arzerra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine administered orally</description>
    <arm_group_label>Idelalisib + Fludarabine</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus administered orally twice daily until disease progression</description>
    <arm_group_label>Idelalisib + Everolimus</arm_group_label>
    <other_name>Afinitor</other_name>
    <other_name>RAD-001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib administered as a subcutaneous injection</description>
    <arm_group_label>Idelalisib + Bortezomib</arm_group_label>
    <other_name>Velcade</other_name>
    <other_name>codenamed PS-341</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorambucil</intervention_name>
    <description>Chlorambucil administered on Days 1-7 every 28 days to allow appropriate therapy for participants with CLL and to coordinate into a cycle period equivalent to other study treatment regimens.</description>
    <arm_group_label>Idelalisib + Chlorambucil</arm_group_label>
    <arm_group_label>Idelalisib + Rituximab + Chlorambucil</arm_group_label>
    <other_name>Leukeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide administered orally</description>
    <arm_group_label>Idelalisib + Rituximab + Lenalidomide</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18

          -  Previously treated with relapsed or refractory disease (refractory defined as not
             responding to a standard regimen or progressing within 6 months of the last course of
             a standard regimen)

          -  Disease status requirement:

               -  For CLL patients, symptomatic disease that mandates treatment as defined by the
                  International Workshop on Chronic Lymphocytic Lymphoma (IWCLL) 2008 criteria

               -  For indolent NHL and MCL patients, measurable disease by CT scan defined as at
                  least 1 lesion that measures &gt; 2 cm in a single dimension

          -  WHO performance status of ≤ 2

          -  For men and women of child-bearing potential, willing to use adequate contraception
             (ie, latex condom, cervical cap, diaphragm, abstinence, etc.) for the entire duration
             of the study.

               -  For Cohort 7 only: Women of child bearing potential must have 2 negative
                  pregnancy tests prior to starting Lenalidomide.

          -  Able to provide written informed consent

        Exclusion Criteria:

          -  Is not a good candidate to receive any of the drugs administered in the study for a
             given disease (idelalisib, bendamustine, rituximab, ofatumumab, fludarabine,
             everolimus, bortezomib, or chlorambucil), according to the clinical judgment of the
             investigator

          -  Patients with atypical immunophenotype with t(11:14) translocation or cyclin D1
             over‑expression (CLL patients only)

          -  Had radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or treatment
             with an investigational product within 4-weeks prior to the baseline disease status
             tests

          -  Had treatment with a short course of corticosteroids for symptom relief within 1‑week
             prior to the baseline disease status tests

          -  Has had an allogeneic hematopoietic stem cell transplant

          -  Has known active central nervous system involvement of the malignancy

          -  Is pregnant or nursing

          -  Has active, serious infection requiring systemic therapy. Patients may receive
             prophylactic antibiotics and antiviral therapy at the discretion of the investigator

          -  Has absolute neutrophil count (ANC) &lt; 1000/µL, unless it is related to underlying CLL,
             MCL or indolent NHL, the latter documented by &gt; 50% infiltration of bone marrow by
             tumor cells

          -  Has platelet count &lt; 75000/µL, unless it is related to underlying CLL, MCL, or iNHL,
             the latter documented by &gt; 50% infiltration of bone marrow by tumor cells

          -  Has serum creatinine ≥ 2.0 mg/dL

               -  For Cohort 7 only: Has creatinine clearance &lt; 60 mL/min

          -  Has serum bilirubin ≥ 2 mg/dL (unless due to Gilbert's syndrome) for patients with
             iNHL or CLL; for patients with MCL, serum bilirubin ≥ 1.5 x upper limit of normal

          -  Has serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≥ 2 x upper
             limit of normal

          -  Has Child-Pugh Class B or C hepatic impairment

          -  Has a positive test for HIV antibodies

          -  Has active hepatitis B or C (confirmed by RNA test). Patients with serologic evidence
             of prior exposure are eligible.

          -  Prior treatment with idelalisib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Jahn, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clearview Cancer Institute</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-5548</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Center</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Star Lodge Cancer Center</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2010</study_first_submitted>
  <study_first_submitted_qc>March 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2010</study_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>non-Hodgkin lymphoma (NHL)</keyword>
  <keyword>mantle cell lymphoma (MCL)</keyword>
  <keyword>phosphatidylinositol 3-kinase</keyword>
  <keyword>bendamustine</keyword>
  <keyword>CD20 mAb</keyword>
  <keyword>rituximab</keyword>
  <keyword>CAL-101</keyword>
  <keyword>Ofatumumab</keyword>
  <keyword>indolent non-Hodgkin lymphoma (iNHL)</keyword>
  <keyword>fludarabine</keyword>
  <keyword>everolimus</keyword>
  <keyword>bortezomib</keyword>
  <keyword>chlorambucil</keyword>
  <keyword>lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Ofatumumab</mesh_term>
    <mesh_term>Idelalisib</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Chlorambucil</mesh_term>
    <mesh_term>Antineoplastic Agents</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunologic Factors</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

